Intranasal Epinephrine (NS –002)
Medical need and size
- Definition: Severe allergic type 1 reaction. Life threatening,
- Prevalence: 1.5 % of the US population suffer an event each •( 500,000 cases annually)
- Cost of treatment 4 B annually
- Mortality rates 1.2 % per episode, 30 % recurrence risk lifetime
- Epinephrine IM or IV is the first line treatment.
Market structure
- Regulatory requirements : 505 b 2 . Comparator: Epipen ,
- Development plan : POC study to start Q 2 2020